FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135505727> ?p ?o ?g. }

• W3135505727 endingPage "501" @default.
• W3135505727 startingPage "490" @default.
• W3135505727 abstract "<h3>Objective:</h3> Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been reported in diverse cancer types, including non-small cell lung cancer (NSCLC). The frequency of <i>FGFR</i> aberrations in Chinese NSCLC patients is therefore of great clinical significance. <h3>Methods:</h3> A total of 10,966 NSCLC patients whose tumor specimen and/or circulating cell-free DNA (cfDNA) underwent hybridization capture-based next-generation sequencing were reviewed. Patients’ clinical characteristics and treatment histories were also evaluated. <h3>Results:</h3> <i>FGFR</i> aberrations, including mutations, fusions, and gene amplifications, were detected in 1.9% (210/10,966) of the population. <i>FGFR</i> abnormalities were more frequently observed in lung squamous cell carcinomas (6.8%, 65/954) than lung adenocarcinomas (1.3%, 128/9,596). <i>FGFR</i> oncogenic mutations were identified in 19 patients (∼0.17%), of which, 68% were male lung squamous cell carcinoma patients. Eleven out of the 19 patients (58%) had concurrent altered PI3K signaling, thus highlighting a potential combination therapeutic strategy of dual-targeting FGFR and PI3K signaling in such patients. Furthermore, <i>FGFR</i> fusions retaining the intact kinase domain were identified in 12 patients (0.11%), including 9 <i>FGFR3-TACC3</i>, 1 <i>FGFR2-INA</i>, 1 novel <i>FGFR4-RAPGEFL1</i>, and 1 novel fusion between the <i>FGFR1</i> and <i>SLC20A2</i> 5′-untranslated regions, which may have caused <i>FGFR1</i> overexpressions. Concomitant <i>EGFR</i> mutations or amplifications were observed in 6 patients, and 4 patients received anti-EGFR inhibitors, in whom <i>FGFR</i> fusions may have mediated resistance to anti-EGFR therapies. <i>FGFR</i> amplification was detected in 24 patients, with the majority being <i>FGFR1</i> amplifications. Importantly, <i>FGFR</i> oncogenic mutations, fusions, and gene amplifications were almost always mutually exclusive events. <h3>Conclusions:</h3> We report the prevalence of <i>FGFR</i> anomalies in a large NSCLC population, including mutations, gene amplifications, and novel <i>FGFR</i> fusions." @default.
• W3135505727 created "2021-03-15" @default.
• W3135505727 creator A5003742311 @default.
• W3135505727 creator A5010398730 @default.
• W3135505727 creator A5013941213 @default.
• W3135505727 creator A5032428632 @default.
• W3135505727 creator A5033848652 @default.
• W3135505727 creator A5041623170 @default.
• W3135505727 creator A5056791076 @default.
• W3135505727 creator A5057674674 @default.
• W3135505727 date "2021-01-01" @default.
• W3135505727 modified "2023-10-17" @default.
• W3135505727 title "Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases" @default.
• W3135505727 cites W1858135205 @default.
• W3135505727 cites W1894751757 @default.
• W3135505727 cites W1960850967 @default.
• W3135505727 cites W2004893350 @default.
• W3135505727 cites W2031597668 @default.
• W3135505727 cites W2092977595 @default.
• W3135505727 cites W2102116016 @default.
• W3135505727 cites W2104812730 @default.
• W3135505727 cites W2107211326 @default.
• W3135505727 cites W2107977954 @default.
• W3135505727 cites W2117122875 @default.
• W3135505727 cites W2118696726 @default.
• W3135505727 cites W2129566355 @default.
• W3135505727 cites W2131271579 @default.
• W3135505727 cites W2136549416 @default.
• W3135505727 cites W2155943701 @default.
• W3135505727 cites W2169752008 @default.
• W3135505727 cites W2170030318 @default.
• W3135505727 cites W2208494337 @default.
• W3135505727 cites W2223869627 @default.
• W3135505727 cites W2467961502 @default.
• W3135505727 cites W2506890042 @default.
• W3135505727 cites W2521908562 @default.
• W3135505727 cites W2570752112 @default.
• W3135505727 cites W2581395526 @default.
• W3135505727 cites W2597742783 @default.
• W3135505727 cites W2598551510 @default.
• W3135505727 cites W2614443510 @default.
• W3135505727 cites W2618618401 @default.
• W3135505727 cites W2724113071 @default.
• W3135505727 cites W2734669213 @default.
• W3135505727 cites W2754439206 @default.
• W3135505727 cites W2790922923 @default.
• W3135505727 cites W2803109366 @default.
• W3135505727 cites W2902322407 @default.
• W3135505727 cites W2964014383 @default.
• W3135505727 cites W3010944770 @default.
• W3135505727 doi "https://doi.org/10.20892/j.issn.2095-3941.2020.0120" @default.
• W3135505727 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8185861" @default.
• W3135505727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33710807" @default.
• W3135505727 hasPublicationYear "2021" @default.
• W3135505727 type Work @default.
• W3135505727 sameAs 3135505727 @default.
• W3135505727 citedByCount "12" @default.
• W3135505727 countsByYear W31355057272022 @default.
• W3135505727 countsByYear W31355057272023 @default.
• W3135505727 crossrefType "journal-article" @default.
• W3135505727 hasAuthorship W3135505727A5003742311 @default.
• W3135505727 hasAuthorship W3135505727A5010398730 @default.
• W3135505727 hasAuthorship W3135505727A5013941213 @default.
• W3135505727 hasAuthorship W3135505727A5032428632 @default.
• W3135505727 hasAuthorship W3135505727A5033848652 @default.
• W3135505727 hasAuthorship W3135505727A5041623170 @default.
• W3135505727 hasAuthorship W3135505727A5056791076 @default.
• W3135505727 hasAuthorship W3135505727A5057674674 @default.
• W3135505727 hasBestOaLocation W31355057271 @default.
• W3135505727 hasConcept C104317684 @default.
• W3135505727 hasConcept C121608353 @default.
• W3135505727 hasConcept C126322002 @default.
• W3135505727 hasConcept C143065580 @default.
• W3135505727 hasConcept C143998085 @default.
• W3135505727 hasConcept C170493617 @default.
• W3135505727 hasConcept C184235292 @default.
• W3135505727 hasConcept C2776256026 @default.
• W3135505727 hasConcept C32619005 @default.
• W3135505727 hasConcept C49418065 @default.
• W3135505727 hasConcept C502942594 @default.
• W3135505727 hasConcept C54355233 @default.
• W3135505727 hasConcept C71924100 @default.
• W3135505727 hasConcept C74373430 @default.
• W3135505727 hasConcept C82867764 @default.
• W3135505727 hasConcept C86803240 @default.
• W3135505727 hasConceptScore W3135505727C104317684 @default.
• W3135505727 hasConceptScore W3135505727C121608353 @default.
• W3135505727 hasConceptScore W3135505727C126322002 @default.
• W3135505727 hasConceptScore W3135505727C143065580 @default.
• W3135505727 hasConceptScore W3135505727C143998085 @default.
• W3135505727 hasConceptScore W3135505727C170493617 @default.
• W3135505727 hasConceptScore W3135505727C184235292 @default.
• W3135505727 hasConceptScore W3135505727C2776256026 @default.
• W3135505727 hasConceptScore W3135505727C32619005 @default.
• W3135505727 hasConceptScore W3135505727C49418065 @default.
• W3135505727 hasConceptScore W3135505727C502942594 @default.
• W3135505727 hasConceptScore W3135505727C54355233 @default.
• W3135505727 hasConceptScore W3135505727C71924100 @default.

• next